This site provides INTERCEPT product information for Health Care Professionals in the United States.

resources

Videos, Webinars, & Podcasts

Back to resources

ASA 2025: IFC in OB Hemorrhage at UCLA

Watch the Replay

Runtime: 13 min

Timely administration of fibrinogen and other key clotting factors is essential to treating coagulopathy associated with fibrinogen deficiency. Access to fibrinogen sources (such as cryo AHF and fibrinogen concentrates) can be challenging given their long wait times, need to reconstitute, cost, wastage and short shelf life. Join us to learn how INTERCEPT® Fibrinogen Complex (IFC) is immediately available* due to its 5-day post thaw shelf life, improving patient access to fibrinogen supplementation during hemorrhage. Hear experts in OB, CV & trauma anesthesia speak to their IFC experiences and how it impacts their patient care.

Jason Hirsch, MD
Medical Director of Obstetric Anesthesiology
UCLA Santa Monica
Associate Clinical Professor, Anesthesiology
University of California, Los Angeles

Dr. Jason Hirsch completed his residency and obstetric anesthesiology fellowship at UCLA. He is currently the Medical Director for Obstetric Anesthesiology at UCLA Santa Monica and started the high-risk anesthesia obstetric service at UCLA. He has a special interest in quality improvement projects related to obstetric hemorrhage requiring massive transfusions and is currently in the process of developing a multidisciplinary response team for such hemorrhages. As a part of this project, Dr. Hirsch is helping to advance OB hemorrhage simulations that involve OBs, nurses, anesthesiologists, blood bank, and clinical lab to make the process of massive transfusion as smooth and efficient as possible.

* INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use.

MKT-EN 00888 v1.0
MKT-EN 00889 v1.0

INTERCEPT® Blood System for Platelets Pathogen Reduction System

INTENDED USE

The INTERCEPT Blood System for Platelets is intended to be used for ex vivo preparation of pathogen-reduced Amicus apheresis platelet components suspended in 65% PAS-3/35% plasma, and Trima apheresis platelet components suspended in 100% plasma in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD).

CONTRAINDICATIONS

Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process.

Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

INTERCEPT® Blood System for Plasma Pathogen Reduction System

INTENDED USE

The INTERCEPT Blood System for Plasma is intended to be used for the ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of transfusion-transmitted infection (TTI), and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD).

CONTRAINDICATIONS

Contraindicated for preparation of plasma intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of plasma intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only INTERCEPT Processing Sets for plasma are approved for use in the INTERCEPT Blood System for Plasma. Use only the INT100 Illuminator for UVA illumination of amotosalen-treated plasma. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any plasma not exposed to the complete INT100 illumination process.

Tubing components and container ports of the INTERCEPT Blood System for Plasma contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approximately 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

Amotosalen-treated plasma may cause the following adverse reaction:

Cardiac Events

In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex

INTENDED USE
The INTERCEPT Blood System for Cryoprecipitation is intended to provide a functionally closed system for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

Pathogen Reduced Cryoprecipitated Fibrinogen Complex is indicated for:

Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
Second-line therapy for von Willebrand disease (vWD).
Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: Should not be used for replacement of factor VIII.

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.

INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Plasma, Cryoprecipitate Reduced

INTENDED USE

The INTERCEPT Blood System for Cryoprecipitation is intended to provide a functionally closed system for the production of Pathogen Reduced Plasma, Cryoprecipitate Reduced.

Pathogen Reduced Plasma, Cryoprecipitate Reduced is indicated for transfusion or therapeutic plasma exchange (TPE) in patients with thrombotic thrombocytopenic purpura (TTP). It may be used to provide coagulation factors, except fibrinogen, factor VIII, factor XIII, and von Willebrand factor (vWF), for transfusion support of patients with appropriate clinical indications.

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

Pathogen Reduced Plasma, Cryoprecipitate Reduced should not be used for replacement of coagulation factors known to be depleted in this product: fibrinogen, factor VIII, vWF and factor XIII.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT® Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Plasma, Cryoprecipitate Reduced.